RNA-targeting drugs behind Roche’s acquisition of Santaris

05-08-2014

RNA-targeting drugs behind Roche’s acquisition of Santaris

ktsdesign / Shutterstock.com

New drugs that target ribonucleic acid (RNA) being developed by Danish biotechnology company Santaris Pharma lie behind the decision by Roche to buy Santaris that was announced yesterday, August 4.


Roche, Santaris, mergers and acquisitions, LNA

LSIPR